AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31139911 — intervention group
Group type: COMPARATOR
Intervention: Patients who visited ≥ 4 physicians before surgery (Group 2)
Number of subjects: 100
Study 29202786 — intervention group
Group type: EXPERIMENTAL
Intervention: PERFECTED enhanced recovery intervention (PERFECT-ER)
Number of subjects: 400
Study 29202786 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 400
Study 23711244 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepilex(®) Border Sacrum and Mepilex(®) Heel dressings applied in the emergency department and maintained throughout ICU stay
Number of subjects: 440
Study 23711244 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepilex(®) Border Sacrum and Mepilex(®) Heel dressings
Number of subjects: 440
Study 25163905 — intervention group
Group type: EXPERIMENTAL
Intervention: Active monitoring
Number of subjects: 1643
Study 25163905 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 1643
Study 25163905 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 1643
Study 21605175 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily application of betamethasone valerate 0.1% corticosteroid cream
Number of subjects: 44
Study 21605175 — intervention group
Group type: COMPARATOR
Intervention: Twice daily application of betamethasone valerate 0.1% corticosteroid cream
Number of subjects: 44
Study 21605175 — intervention group
Group type: COMPARATOR
Intervention: Urea-containing moisturizer (substituted for corticosteroid cream in the morning)
Number of subjects: 44
Study 19016342 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg BH(4)/kg body weight
Number of subjects: 17
Study 19016342 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg BH(4)/kg body weight
Number of subjects: 17
Study 19016342 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg BH(4)/kg body weight
Number of subjects: 17
Study 17283006 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA
Number of subjects: 205
Study 15028243 — intervention group
Group type: EXPERIMENTAL
Intervention: [(11)C]L‐deprenyl (DEP)
Number of subjects: 0
Study 15028243 — intervention group
Group type: COMPARATOR
Intervention: [(11)C]clorgyline (CLG)
Number of subjects: 0
Study 11597936 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering therapy (niacin 2.5 g/d, lovastatin 40 mg/d, colestipol 20 g/d) for 10 years
Number of subjects: 16
Study 11597936 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated CAD patients)
Number of subjects: 16
Study 11597936 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering therapy
Number of subjects: 16
Study 11597936 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study 9585292 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 10
Study 9585292 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375% bupivacaine
Number of subjects: 10
Study 8033381 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% metronidazole gel
Number of subjects: 96
Study 8033381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 2586436 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 intratumoral injection (group A)
Number of subjects: 395
Study 2586436 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 395
Study 195411 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (COMB)
Number of subjects: 35
Study 195411 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (BACO)
Number of subjects: 35
Study 29635520 — intervention group
Group type: EXPERIMENTAL
Intervention: BRYAN® Cervical Disc arthroplasty
Number of subjects: 0
Study 29635520 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 0
Study 29635520 — intervention group
Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 0
Study 29635520 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined BRYAN® and Prestige disc groups
Number of subjects: 0
Study 29635520 — intervention group
Group type: COMPARATOR
Intervention: Combined ACDF groups
Number of subjects: 0
Study 28863555 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral hearing aid users with broad binaural pitch fusion
Number of subjects: 0
Study 25627340 — intervention group
Group type: EXPERIMENTAL
Intervention: GPi deep brain stimulation (DBS)
Number of subjects: 235
Study 25627340 — intervention group
Group type: EXPERIMENTAL
Intervention: STN deep brain stimulation (DBS)
Number of subjects: 235
Study 25627340 — intervention group
Group type: COMPARATOR
Intervention: Both GPi and STN DBS
Number of subjects: 235
Study 23969797 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin plus uterine massage
Number of subjects: 1170
Study 23969797 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin only
Number of subjects: 1170
Study 21954647 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 0
Study 21954647 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined guidance of ultrasound and nerve stimulator
Number of subjects: 0
Study 21954647 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulator guidance
Number of subjects: 0
Study 19386740 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fat (H-F) diet (30% of energy as carbohydrate and 55% as fat)
Number of subjects: 7
Study 19386740 — intervention group
Group type: COMPARATOR
Intervention: High-Carbohydrate (H-CHO) diet (60% of energy as carbohydrate and 25% as fat)
Number of subjects: 7
Study 16414235 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m² and Docetaxel 35 mg/m²
Number of subjects: 68
Study 15319108 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable pins (PLLA)
Number of subjects: 62
Study 15319108 — intervention group
Group type: COMPARATOR
Intervention: Kirschner wires
Number of subjects: 62
Study 11175583 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐methyl‐glucamine (GL)
Number of subjects: 63
Study 11175583 — intervention group
Group type: COMPARATOR
Intervention: BP88 Sodium Stibogluconate (SS)
Number of subjects: 63
Study 9274702 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (100 micrograms)
Number of subjects: 25
Study 9274702 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-6 (1 microgram/kg)
Number of subjects: 25
Study 9274702 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH + GHRP-6
Number of subjects: 25
Study 9274702 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 25
Study 8361250 — intervention group
Group type: EXPERIMENTAL
Intervention: Contract ADHC
Number of subjects: 163
Study 8361250 — intervention group
Group type: COMPARATOR
Intervention: VA-ADHC
Number of subjects: 163
Study 8361250 — intervention group
Group type: COMPARATOR
Intervention: Customary care
Number of subjects: 163
Study 3718600 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (DPH) preparations A (tablet) and B (buffered solution) containing 50 mg DPH-HCl
Number of subjects: 12
Study 3718600 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation C containing 31 mg DPH-HCl and 23 mg 8-chlorotheophylline
Number of subjects: 12
Study 3718600 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination with 8-chlorotheophylline
Number of subjects: 12
Study 3718600 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic measurements of vigilance
Number of subjects: 12
Study 31969275 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain intervention (four home visits and 12 telephone calls over 12 weeks, incorporating physical activity, healthy diet, social activity, and brief cognitive restructuring)
Number of subjects: 78
Study 31969275 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 78
Study 30938120 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA protector
Number of subjects: 143
Study 30938120 — intervention group
Group type: COMPARATOR
Intervention: LMA traditional
Number of subjects: 143
Study 27834191 — intervention group
Group type: EXPERIMENTAL
Intervention: Video decision aid and text message reminder
Number of subjects: 64
Study 27834191 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 64
Study 26861425 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin 5% cream
Number of subjects: 120
Study 26861425 — intervention group
Group type: COMPARATOR
Intervention: Lindane 1% lotion
Number of subjects: 120
Study 23106243 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg misoprostol
Number of subjects: 310
Study 23106243 — intervention group
Group type: COMPARATOR
Intervention: 800 μg misoprostol
Number of subjects: 310
Study 21597409 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam 12 g
Number of subjects: 88
Study 21597409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 21597409 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Piracetam and Placebo)
Number of subjects: 88
Study 18155382 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue hook
Number of subjects: 20
Study 18155382 — intervention group
Group type: COMPARATOR
Intervention: Trauma scissors
Number of subjects: 20
Study 16675186 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal LMA (MLP)
Number of subjects: 120
Study 16675186 — intervention group
Group type: COMPARATOR
Intervention: Classic laryngeal mask airway (MLC)
Number of subjects: 120
Study 15010152 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone tube nerve repair
Number of subjects: 30
Study 15010152 — intervention group
Group type: COMPARATOR
Intervention: Routine microsurgical repair
Number of subjects: 30
Study 11682384 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4 microg/kg
Number of subjects: 10
Study 11682384 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study 9129038 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose cytosine arabinoside and daunomycin + rhG‐CSF
Number of subjects: 211
Study 9129038 — intervention group
Group type: EXPERIMENTAL
Intervention: MDR1(+) secondary AML patients with unfavorable cytogenetics
Number of subjects: 211
Study 9129038 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfavorable cytogenetics
Number of subjects: 211
Study 9129038 — intervention group
Group type: EXPERIMENTAL
Intervention: MDR1 expression
Number of subjects: 211
Study 9129038 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary AML
Number of subjects: 211
Study 9129038 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant disease
Number of subjects: 211
Study 7948961 — intervention group
Group type: EXPERIMENTAL
Intervention: C2T (2 g ceftazidime every 8 h plus 5 mg/kg/day tobramycin)
Number of subjects: 150
Study 7948961 — intervention group
Group type: COMPARATOR
Intervention: C1T (1 g ceftazidime every 8 h plus 5 mg/kg/day tobramycin)
Number of subjects: 150
Study 3361022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg/kg/day during the first 3 days
Number of subjects: 25
Study 3361022 — intervention group
Group type: COMPARATOR
Intervention: Not receiving dexamethasone (control group)
Number of subjects: 25
Study 31915047 — intervention group
Group type: EXPERIMENTAL
Intervention: Second Propess® placement followed by oxytocin (Syntocinon®) if necessary
Number of subjects: 360
Study 31915047 — intervention group
Group type: COMPARATOR
Intervention: Direct oxytocin injection
Number of subjects: 360
Study 31915047 — intervention group
Group type: EXPERIMENTAL
Intervention: Second Propess® placement
Number of subjects: 360
Study 29098341 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 100 μg
Number of subjects: 20
Study 29098341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27112113 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Motivational Interviewing (AMI)
Number of subjects: 51
Study 27112113 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 51
Study 25325892 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser group
Number of subjects: 20
Study 25325892 — intervention group
Group type: COMPARATOR
Intervention: Manual group
Number of subjects: 20
Study 22545755 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component program including classroom curriculum, school environment support, family involvement, and fun programs/events.
Number of subjects: 8
Study 22545755 — intervention group
Group type: COMPARATOR
Intervention: Usual health and physical education curriculum with no additional intervention program.
Number of subjects: 8
Study 20338496 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal medical therapy
Number of subjects: 2287
Study 18250126 — intervention group
Group type: EXPERIMENTAL
Intervention: MELD score > or = 18
Number of subjects: 256
Study 18250126 — intervention group
Group type: EXPERIMENTAL
Intervention: MELD score > or = 18 and > or = 4 units of PRBCs transfused
Number of subjects: 256
Study 18250126 — intervention group
Group type: EXPERIMENTAL
Intervention: MELD score > or = 18 and active bleeding at index endoscopy
Number of subjects: 256
Study 18250126 — intervention group
Group type: EXPERIMENTAL
Intervention: Variceal re‐bleeding
Number of subjects: 256
Study 18250126 — intervention group
Group type: EXPERIMENTAL
Intervention: MELD score
Number of subjects: 256
Study 18250126 — intervention group
Group type: EXPERIMENTAL
Intervention: Units of packed red blood cells (PRBCs) transfused in the first 24 h
Number of subjects: 256
Study 18250126 — intervention group
Group type: EXPERIMENTAL
Intervention: Clot on a varix
Number of subjects: 256
Study 16125994 — intervention group
Group type: EXPERIMENTAL
Intervention: Backpack loads of 0, 7.5, 10, 12.5 and 15% body weight
Number of subjects: 50
Study 16125994 — intervention group
Group type: COMPARATOR
Intervention: Adolescent idiopathic scoliosis (AIS)
Number of subjects: 50
Study 16125994 — intervention group
Group type: EXPERIMENTAL
Intervention: Backpack loads (7.5% body weight) in AIS group
Number of subjects: 50
Study 16125994 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 50
Study 11898510 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptans (specific dosage and duration not mentioned)
Number of subjects: 0
Study 11898510 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified-care model for migraine management
Number of subjects: 0
Study 11898510 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive medical and psychologic evaluation for tension-type headaches
Number of subjects: 0
Study 9579834 — intervention group
Group type: EXPERIMENTAL
Intervention: BCDT with IL-2/IFN-alpha
Number of subjects: 65
Study 9579834 — intervention group
Group type: COMPARATOR
Intervention: BCDT alone
Number of subjects: 65
Study 8037261 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sodium lactate infusion
Number of subjects: 15
Study 8037261 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 15
Study 3378983 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained endurance athletes (T)
Number of subjects: 13
Study 3378983 — intervention group
Group type: COMPARATOR
Intervention: Untrained individuals (UT)
Number of subjects: 13
Study 28958504 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilotumumab plus epirubicin, cisplatin, and capecitabine
Number of subjects: 609
Study 28958504 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus epirubicin, cisplatin, and capecitabine
Number of subjects: 609
Study 28958504 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilotumumab
Number of subjects: 609
Study 28958504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 609
Study 23030252 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine (10 mg)
Number of subjects: 5
Study 20801047 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative proprioceptive training (TG)
Number of subjects: 0
Study 20801047 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study 20801047 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TG and CG)
Number of subjects: 0
Study 19216936 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg, i.e., two sticks of Stay Alert gum) administered at 0100, 0300, 0500, and 0700 during nights 2, 3, and 4
Number of subjects: 18
Study 19216936 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered at the same times as caffeine
Number of subjects: 18
Study 17664481 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor sclerosis
Number of subjects: 158
Study 15076260 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 62
Study 15076260 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 62
Study 11881131 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg once-daily for four weeks, titrated to 80 mg if necessary
Number of subjects: 71
Study 11881131 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg once-daily for four weeks, titrated to 20 mg if necessary
Number of subjects: 71
Study 9663917 — intervention group
Group type: EXPERIMENTAL
Intervention: Active therapy (n=16)
Number of subjects: 30
Study 9663917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7824673 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic patients
Number of subjects: 36
Study 7824673 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 36
Study 7824673 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 2687135 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteolytic enzymes administered endotracheally in pre- and postoperative periods
Number of subjects: 259
Study 2687135 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 259
Study 31851093 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day dual therapy (esomeprazole 20 mg and amoxicillin 750 mg, q.i.d.)
Number of subjects: 208
Study 31851093 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day dual therapy (esomeprazole 20 mg and amoxicillin 1000 mg, t.i.d.)
Number of subjects: 208
Study 30866559 — intervention group
Group type: EXPERIMENTAL
Intervention: Days with asthma presentations exceeding four standard deviations from the mean (case days)
Number of subjects: 0
Study 30866559 — intervention group
Group type: COMPARATOR
Intervention: Days with asthma presentations less than one standard deviation from the mean (control days)
Number of subjects: 0
Study 30866559 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of epidemic thunderstorm asthma risk
Number of subjects: 0
Study 28511713 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 900
Study 28511713 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine-artesunate (MQAS)
Number of subjects: 900
Study 28511713 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHAPQ)
Number of subjects: 900
Study 25886958 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic osteochondroplasty with/without labral repair
Number of subjects: 220
Study 25886958 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic lavage of the hip joint
Number of subjects: 220
Study 23868885 — intervention group
Group type: EXPERIMENTAL
Intervention: Littmann 3200 electronic stethoscope
Number of subjects: 100
Study 23868885 — intervention group
Group type: EXPERIMENTAL
Intervention: Littmann Cardiology III acoustic stethoscope
Number of subjects: 100
Study 23868885 — intervention group
Group type: COMPARATOR
Intervention: Holtex Ideal acoustic stethoscope
Number of subjects: 100
Study 23868885 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between Littmann 3200 and Littmann Cardiology III
Number of subjects: 100
Study 22090660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 18624
Study 22090660 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 18624
Study 19104814 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (2,000 mg/(m(2) day) on days 1-14) and Irinotecan (250 mg/m(2) every 3 weeks)
Number of subjects: 29
Study 16508400 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib and valdecoxib
Number of subjects: 1062
Study 16508400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1062
Study 15731605 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% spinal ropivacaine
Number of subjects: 97
Study 15731605 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% spinal levobupivacaine
Number of subjects: 97
Study 15731605 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% spinal bupivacaine
Number of subjects: 97
Study 15731605 — intervention group
Group type: COMPARATOR
Intervention: ropivacaine
Number of subjects: 97
Study 15731605 — intervention group
Group type: COMPARATOR
Intervention: levobupivacaine
Number of subjects: 97
Study 15731605 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine
Number of subjects: 97
Study 15731605 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine and levobupivacaine
Number of subjects: 97
Study 12930013 — intervention group
Group type: EXPERIMENTAL
Intervention: Large middle meatal antrostomy
Number of subjects: 60
Study 12930013 — intervention group
Group type: COMPARATOR
Intervention: Undisturbed maxillary ostium
Number of subjects: 60
Study 12930013 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 10193918 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 0
Study 7852519 — intervention group
Group type: EXPERIMENTAL
Intervention: hGH replacement therapy (12.5 micrograms/kg BW, self-administered daily sc)
Number of subjects: 20
Study 7852519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2094113 — intervention group
Group type: EXPERIMENTAL
Intervention: Etofenamate 10% cream
Number of subjects: 60
Study 2094113 — intervention group
Group type: COMPARATOR
Intervention: Oral naproxen
Number of subjects: 60
Study 728318 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxyphenisatin
Number of subjects: 10
Study 728318 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracene purgatives
Number of subjects: 10
Study 728318 — intervention group
Group type: EXPERIMENTAL
Intervention: (+)-norpseudoephedrine
Number of subjects: 10